Amarin Corp. PLC (AMRN) Shares Up 5.2%
Shares of Amarin Corp. PLC (NASDAQ:AMRN) shot up 5.2% during mid-day trading on Friday . The company traded as high as $3.32 and last traded at $3.25, with a volume of 2,355,318 shares traded. The stock had previously closed at $3.09.
A number of brokerages recently issued reports on AMRN. Jefferies Group restated a “buy” rating on shares of Amarin Corp. PLC in a research report on Tuesday, May 31st. Zacks Investment Research lowered shares of Amarin Corp. PLC from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Amarin Corp. PLC in a report on Monday, May 9th.
The company’s market cap is $583.18 million. The firm’s 50-day moving average price is $2.67 and its 200 day moving average price is $1.95.
Amarin Corp. PLC (NASDAQ:AMRN) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The company earned $32.82 million during the quarter, compared to analyst estimates of $29.97 million. The company’s revenue was up 85.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.15) earnings per share. Equities research analysts expect that Amarin Corp. PLC will post ($0.46) earnings per share for the current year.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.